Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02386423
Other study ID # Sorg1
Secondary ID
Status Completed
Phase N/A
First received March 2, 2015
Last updated March 5, 2015
Start date April 2009
Est. completion date November 2011

Study information

Verified date March 2015
Source Lake Erie Research Institute
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and efficacy of RESTIFFIC™, a foot wrap that produces adjustable targeted pressure on specific muscles in the feet, to reduce the symptoms of moderate to severe primary Restless Legs Syndrome.


Description:

Restless legs syndrome (RLS), or Willis-Ekbom Disease, is a neurologic disorder causing unpleasant sensations and an urge to move the legs when the person is at rest. The sensations are relieved by movement. Loss of sleep associated with RLS can cause extreme fatigue, affecting concentration, which may produce anxiety and depression, resulting in a poor quality of life. Prevalence in the general population is 5% to 10%. In approximately 3%, symptoms are so severe that treatment is sought. Potent drugs, such as opioids, central nervous system depressants, anticonvulsants, and dopamine agonists have been used to ease symptoms, each with several side effects.

Anecdotal evidence suggested that pressure on specific foot muscles decreases symptoms of moderate to severe primary restless legs syndrome. In the RESTIFFIC™ study, patients served as their own negative controls, wearing the RESTIFFIC™ devices intermittently, while completing surveys related to RLS throughout the study. Physicians also completed surveys related to quality of life. Meta-analysis was used to compare RESTIFFIC™ to historic reports of ropinirole and placebo pill. Demographics, disease severity,inclusion/exclusion criteria, assessment tools were similar among studies.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date November 2011
Est. primary completion date April 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

Otherwise healthy adults between the ages of 18 and 75 years who were diagnosed with moderate to severe RLS were recruited from Erie and the surrounding regions. The patient was examined by the physician and screened using the medical history, the International RLS study group diagnostic criteria, and International RLS Study (IRLSS) Rating Scale.

To be included, patients had to have: (1) a total score of 15 or greater on the International RLS Rating Scale; (2) evening and nighttime symptoms with sleep impairment (by self-report) due to RLS; and (3) RLS for at least six months with symptoms at least two to three times per week. The potential was for at least 12 and as many as 42 episodes of RLS during the treatment period.

Exclusion Criteria:

The patient was excluded if he/she had any serious medical conditions or conditions that may have presented a safety concern or that may have impacted efficacy assessment, eg, taking drugs like antidepressants known to affect RLS. Medical conditions included, but were not limited to: claudication, nerve problems, fragile, thin skin, impaired wound healing; poor circulation, injury to feet or legs, movement problems, inability to sit still or remain motionless, involuntary movements similar to a tic, sleep disorders, parasomnias involving abnormal movements, narcolepsy, obstructive sleep apnea, nighttime discomfort not due to RLS, secondary RLS, or Parkinson's Disease. Patients on drug treatment for RLS must have been discontinued treatment for at least 30 days. (Note: None of our patients were on drug treatment for RLS.) Through history and physical examination, the physician distinguished RLS from other disorders such as periodic Limb Movement Disorder (footnote 5)

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
RESTIFFIC™ Brand Pressure Application System
The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).

Locations

Country Name City State
United States Baycity Associated in Podiatry Inc Erie Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Lake Erie Research Institute

Country where clinical trial is conducted

United States, 

References & Publications (3)

Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY; TREAT RLS US Study Group. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006 Jan;81(1):17-27. — View Citation

Trenkwalder C, Garcia-Borreguero D, Montagna P, Lainey E, de Weerd AW, Tidswell P, Saletu-Zyhlarz G, Telstad W, Ferini-Strambi L; Therapy with Ropiunirole; Efficacy and Tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):92-7. — View Citation

Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K; TREAT RLS 2 (Therapy with Ropinirole: Efficacy And Tolerability in RLS 2) Study Group. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004 Dec;19(12):1414-23. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Meta-analysis used to compare change in IRLSS scores in RESTIFFIC to change in IRLSS scores for ropinirole and placebo pill (historic reports) Baseline to end of study No
Other Number and type of adverse events as a measure of safety and tolerability of RESTIFFIC™ vs ropinirol and placebo (historic reports) Baseline to study end. Yes
Primary Change in International Restless Legs Syndrome Study Rating Scale Change in International RLS Study Group (IRLSS) Rating Scale from baseline to Day 56 Study end No
Secondary Clinical Global Impression Scale Four CGI Scales, one each on Days, 1, 29, 36, and 57 No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01931878 - Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome. Phase 2
Completed NCT01672502 - Fire Fighter Fatigue Management Program: Operation Fight Fatigue N/A
Completed NCT02085720 - Prevalence of OSAS in Chinese Elderly and Its CPAP Compliance N/A
Completed NCT03337529 - Restless Legs Syndrome in Hemodialysis Patients N/A
Completed NCT01245777 - Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy Phase 4
Completed NCT01617044 - Probiotics in the Treatment of Iron Deficiency in Children With Restless Leg Syndrome Phase 2
Recruiting NCT02016638 - Sleep Quality in Pregnancy and Its Impact on Pregnancy Outcomes N/A
Completed NCT01988129 - Fire Fighter Fatigue Management Program: Operation Healthy Sleep N/A
Completed NCT00949858 - New Data Analysis Methods for Actigraphy in Sleep Medicine N/A
Completed NCT03818243 - Circadian Character of Food Compulsions and Impulses Control Disorders in Parkinsonian Patients With and Without Resting Leg Syndrome N/A
Completed NCT00872248 - Neuraxial Anesthesia and Restless Leg Syndromes in Cesarean N/A
Completed NCT00673088 - A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions N/A
Completed NCT00674310 - A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions N/A
Completed NCT01538147 - Restless Leg Syndrome and Severe Preeclampsia N/A
Terminated NCT02117076 - Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome Phase 4
Recruiting NCT06233773 - The Effect of Kinesio Taping and Manual Lymph Drainage on Pregnant Women With Restless Legs Syndrome N/A